Sign in
Taking people in United StatesPhase 3

Tests semaglutide for heart and kidney effects in adults with type 1 diabetes

Tests semaglutide against placebo in adults with type 1 diabetes.

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora and Seattle, United StatesSee the 2 sites
Trial code
Registry title
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Status
Recruiting
Phase
Phase 3
People taking part
60 people, planned
Started
21 Jun 2023
Expected to end
1 Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Semaglutide Pen Injector
  • Placebo
Record updated
4 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-49 with type 1 diabetes who use an insulin pump or automated insulin delivery. It tests semaglutide's effects on the heart, kidneys and insulin sensitivity.

Age
18 to 49 years
Sex
All sexes
Disease stage
Type 1 diabetes confirmed by positive T1D antibodies, or a clinical diagnosis with insulin needed since diagnosis. Kidney function eGFR ≥ 45 ml/min/1.73m2. BMI 20-45 kg/m2.
Earlier treatment
Must use an insulin pump or automated insulin delivery system. Doses of heart and kidney drugs (e.g., ACEi, ARB, statins, diuretics) must be stable.
Biomarker or test result
Positive type 1 diabetes-associated antibody(ies), or a clinical diagnosis of type 1 diabetes plus insulin need since diagnosis.

Main reasons for not taking part

  • HbA1c >9% (75 mmol/mol), recent diabetic ketoacidosis or hospitalization
  • Current or planned pregnancy, or nursing
  • History or family history of medullary thyroid carcinoma, MEN2 or pancreatitis
  • Other non-insulin diabetes medications, insulin sensitizing medications or systemic steroids in the past 3 months
  • Uncontrolled thyroid disease or high blood pressure (≥ 160/100 mm Hg despite optimal therapy)

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age 18-49 years
  • 1) T1D diagnosis defined as positive T1D-associated antibody(ies) or 2) a clinical diagnosis of T1D plus insulin requirement since diagnosis
  • Insulin pump or automated insulin delivery systems
  • Estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73m2
  • Stable doses of drugs altering cardiovascular and renal function (e.g., Angiotensin-Converting Enzyme Inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), statins, diuretics)
  • BMI 20-45 kg/m2
  • Adequate contraceptive method for females

Who cannot take part

  • Major congenital heart disease, anemia, severe non-proliferative retinopathy, proliferative retinopathy
  • History/family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2), pancreatitis
  • Uncontrolled thyroid disease or hypertension (HTN) (≥ 160/100 mm Hg despite optimal therapy)
  • Use of other non-insulin diabetes medications, insulin sensitizing medications, or systemic steroids in past 3 months
  • Significant systemic illness such as cancer
  • MRI or PAH contraindications (only exclusionary to MRI and PAH procedures), GLP-1RA allergy
  • HbA1c >9%, recent diabetic ketoacidosis (DKA) or hospitalization
  • Shellfish/iodine allergy (only exclusionary to iohexol clearance procedure)
  • Current/planned pregnancy or nursing
  • Use of atypical antipsychotics

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 49 years old?

Where in United States

  • University of Colorado Anschutz Medical CampusAurora, United StatesContact: Kyla BestTaking people
  • University of Washington Medicine Diabetes Institute (UWMDI)Seattle, United StatesContact: Amanda BardTaking people

About the trial

What the trial wants to find out

This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.

The 2 groups in the trial

  • SemaglutideTreatment being tested

    Participants will receive 0.25 mg once weekly semaglutide injection for 4 weeks. Participants will receive 0.50 mg once weekly semaglutide injection for 4 weeks. Participants will receive 1.0 mg once weekly semaglutide injection for 6 months.

    Treatment: Semaglutide Pen Injector

  • PlaceboPlacebo, for comparison

    Participants will receive 0.25 mg once weekly placebo injection for 4 weeks. Participants will receive 0.50 mg once weekly placebo injection for 4 weeks. Participants will receive 1.0 mg once weekly placebo injection for 6 months.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Plain-language title
Tests semaglutide for heart and kidney effects in adults with type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05819138, who can take part
Record updated
4 March 2026